Abstract:Objective: To investigate the efficacy of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) (PLGA) microspheres on Hep-2 laryngeal squamous cell xenografts in nude mice. Methods: The solid tumor model bearing Hep-2 laryngeal squamous cell carcinoma was established in BALB/c nude mice. The model group was given with different therapies. The tumor size and tumor weight were recorded in all of the experimental groups. The tumor inhibition rate (IR) and tumor volume tripling time (TT) were calculated. The counts of microvessel density (MVD), expressions of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in xenografts were examined by Envision™ immunohistological method. Results: Twenty-one days after treatment, the tumor size and tumor weight of the paclitaxel-treated groups were significantly decreased (P < 0.05) and the TTs were significantly prolonged (P < 0.01) compared with the saline control group. The TT of the group receiving intratumoral injection of paclitaxel PLGA microspheres at a low dose was significantly longer compared with the group receiving intratumoral (i. t.) or intraperitoneal (i. p.) injection of paclitaxel (P <0.05). The TT of the group receiving intratumoral injection of paclitaxel microspheres at a high dose was significantly increased compared with the other paclitaxel-treated groups (P < 0.01). The tumor inhibition rates of paclitaxel intraperitoneal or intratumoral injection groups were 35.99% and 39.37%, respectively; and they were 47.83% and 59.90% for paclitaxel microsphere intratumoral injection groups at low and high doses, respectively. PLGA blank microspheres had no effect on the tumor growth. No significant toxic reactions were observed in the experiment. The counts of MVD and immunoreactivity of bFGF and VEGF in the paclitaxel-treated groups were significantly decreased compared with the saline control group (P < 0.05). The intratumoral injection of paclitaxel microspheres markedly reduced bFGF level and showed stronger anti-angiogenic activity in comparison with i. p. and i. t. administration of paclitaxel injection (P < 0.01). Conclusion: Direct administration of polymeric drug control release system into local tumor bodies had a foreground for the treatment of laryngeal squamous cell carcinoma.

In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Egfr-Targeted Poly(Ethylene Glycol)-Distearoylphosphatidylethanolamine Micelle Loaded with Paclitaxel for Laryngeal Cancer: Preparation, Characterization and in Vitro Evaluation

Preparation of paclitaxel loaded PLGA microspheres and its efficacy in Hep-2 laryngeal squamous cell carcinoma-bearing nude mice

Experimental study on effects of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) micro-spheres on Hep-2 laryngeal squamous cell carcinoma xenografts in nude mice

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells

Photo-crosslinked Poly(ethylene Glycol)-B-poly(ϵ-caprolactone) Nanoparticles for Controllable Paclitaxel Release

Preparation and in Vitro Evaluation of Paclitaxel-Loaded Poly(lactide-co-glycolide) Nanoparticles

Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance

Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer.

PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.

Enhanced Oral Bioavailability of Paclitaxel Formulated in Vitamin E-TPGS Emulsified Nanoparticles of Biodegradable Polymers: in Vitro and in Vivo Studies

Preparation and Evaluation of Paclitaxel-Loaded Nanoparticle Incorporated with Galactose-Carrying Polymer for Hepatocyte Targeted Delivery.

Metronomic paclitaxel-loaded mPEG–PLA nanoparticles show enhanced anti-tumor efficacy compared to maximum tolerated dose administration

Evaluating Inhibitory Effects of Paclitaxel and Vitamin D3 Loaded Poly Lactic Glycolic Acid Co-Delivery Nanoparticles on the Breast Cancer Cell Line

Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.

The Efficacy and Safety of Polyethylene Glycol Cholesterol- and Tocopherol Polyethylene Glycol 1000 Succinate-Modified Transforming Growth Factor β1 Small Interfering RNA Lipid Nanoparticles in the Treatment of Paclitaxel-Resistant Non-Small-Cell Lung Cancer

Antitumor Efficiency of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate-b-Poly(ε-caprolactone-<I>ran</I>-lactide) Nanoparticle-Based Delivery of Docetaxel in Mice Bearing Cervical Cancer

High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-g-dextran micelles to efficient cancer therapy